Coverage Evaluation Survey for Lymphatic Filariasis Mass Drug Administration Campaign, 2022

2023, WHO

In 2017, WHO recommended an alternate strategy to accelerate Lymphatic Filariasis (LF) elimination using a triple drug regimen, Ivermectin, diethylcarbamazine (DEC) and Albendazole (IDA) for mass drug administration.  Following this recommendation, triple drug regimen for endemic districts was adopted in 2019. EDCD introduced triple drug regimen in five districts (Morang, Kapilvastu, Dang, Banke, Kailali) from 2022. This survey estimated mass drug administration coverage, validate reported coverage rates and identify reasons for non-compliance. The survey also detected problems with the supply chain and distribution systems (programs reach), as well as measured coverage in specific population.